Dh, there's a few I don't trust, and Roth is one of them. Some companies seem to put out buy ratings and high price targets, just to drive a stock up so they can sell (that's my opinion, I dont have facts to back that up). Needham on the other hand is legit in my opinion. Real company not playing games. I'll take their $18 price target, and be happy with it. At least for now. We all know this thing is headed much, much higher if we get approval for any of the indications they're going after. And a buyout offer from GW Pharma is always a possibility as well. Good times ahead for patient shareholders.
News 
Market Data 
Discover 
